A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease

Clinical Neuropharmacology

Volumn 21, Issue 2, 1998, Pages 101-107

  Brooks, David J ^a   Abbott, Richard J ^b   Lees, Andrew J ^c   Martignoni, Emilia ^d   Philcox, Derek V ^e   Rascol, Olivier ^f   Roos, Raymond A C ^g   Sagar, Harvey J ^h  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

^c MIDDLESEX HOSPITAL   (United Kingdom)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f INSERM   (France)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

De novo; Parkinson's Disease; Ropinirole

Indexed keywords

DOPAMINE 2 RECEPTOR STIMULATING AGENT; ROPINIROLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT OUTCOME; VERTIGO;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PARKINSON DISEASE; RECEPTORS, DOPAMINE D2; TREATMENT OUTCOME;

EID: 0031924380     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with L-dopa. N Engl J Med 1969;280: 337-45.
2. Lesser RP, Fahn S, Snider SR, Cote U, Isgreen WP, Barrett RE. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979;29:1253-60.
3. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease: clinical aspects. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworth Scientific, 1982:96-122.
4. Nutt JG. Levodopa-induced dyskinesia. Neurology 1990;40:340-5.
5. Mouradian MM, Juncos, JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease; central pathophysiological mechanisms, part II. Ann Neurol 1988;24:372-8.
6. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992;59:1609-23.
7. Olanow CW. A rationale for rnonoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease. Mov Disord 1993;8 (suppl 1):S1-7.
8. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993;8:129-33.
9. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC12 cells by L-dopa: implications for the treatment of Parkinson's disease. J Clin Invest 1995;95:2458-64.
10. Hefti F, Melamed E, Bahwan J, Wurtman RJ. Long-term administration of L-dopa does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-5.
11. Perry TL, Young VW, Ito M, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-dopa and carbidopa chronically. J Neurochem 1984;43:990-3.
12. Quinn N, Parkes JD, Janota I, Marsden CD. Preservation of substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four year period. Mov Disord 1986;1:65-8.
13. Libman I, Gawel MJ, Riopelle RJ, Bouchard S. A comparison of bromocriptine (Parlodel® and levodopa-carbidopa (Sinemet®) for the treatment of 'de novo' Parkinson's disease patients. Can J Neurol Sci 1987;14:576-80.
14. Montastruc JL, Rascol O, Rascol A. A randomized controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry 1989;52:773-5.
15. Rinne UK. Dopamine agonists as primary treatment in Parkinson's diseases. Adv Neurol 1986;45:519-23.
16. Stem GM, Lees AJ. Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson's disease. Adv Neurol 1983; 37:17-21.
17. Grimes JD, Delgado MR. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease. Clin Neuropharmacol 1985; 8:73-7.
18. Nakanishi T, Iwata M, Goto I, et al. Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients: final report. Eur Neurol 1992;32(suppl 1)):9-22.
19. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year foifow-yp. Neurology 1987;37:826-8.
20. Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 1989;39:336-9.
21. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-8.
22. 2 agonist. Pharmacol Biochem Behav 1991;38:147-54.
23. Vidailhet MJ, Bonnet AM, Belal S, Dubois B, Marle C, Agid Y. Ropinirole without L-dopa in Parkinson's disease. Lancet 1990;336: 316-7.
24. 2 agonist SK&F 101468. Lancet 1989;1:1445-6.
25. Kleedorfer B, Stern GM, Lees AJ. Ropinirole (SK&F 101468) in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:938.
26. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996; 19:234-45.
27. Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Raseol O, Stocchi F, on behalf of the 053 study group. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. Mov Disord 1998;13:(in press).
28. Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F, on behalf of the 056 study group. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year L-dopa-controlled study. Mov Disord 1998;13:(in press).
29. Boothman BR, Spokes EGS. Pharmacokinetic data for ropinirole. Lancet 1990;2:814.
30. Kreider MM, Knox S, Gardiner D, Wheadon D. A multicenter double-blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease [Abstract]. Neurology 1996;46(suppl 2):A475.